EUVIMEDEUVIMED entdecken
Open Access

γ′ fibrinogen levels as a biomarker of COVID-19 respiratory disease severity

Lucy Z Kornblith, Bindhya Sadhanandhan, Sreepriya Arun, Rebecca Long, Alicia J Johnson, Jamie Noll, C N Ramchand, John K Olynyk, David H Farrell

Blood Cells, Molecules, and Diseases · 2023

DOI: 10.1016/j.bcmd.2023.102746 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood Cells, Molecules, and Diseases, 2023. Verfasst von Lucy Z Kornblith und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of California, San Francisco, CA, USA. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Coronavirus disease 2019 (COVID-19) is characterized by a pro-inflammatory state associated with organ failure, thrombosis, and death. We investigated a novel inflammatory biomarker, γ' fibrinogen (GPF), in 103 hospitalized patients with COVID-19 and 19 healthy controls. We found significant associations between GPF levels and the severity of COVID-19 as judged by blood oxygen saturation (SpO2). The mean level of GPF in the patients with COVID-19 was significantly higher than in controls (69.8 (95 % CI 64.8-74.8) mg/dL compared with 36.9 (95 % CI 31.4-42.4) mg/dL, p 93 %, GPF 62.5 (95 % CI 55.0-70.0) mg/dL, p = 0.01, AUC of 0.68, 95 % CI 0.57-0.78; Youden's index cutpoint 62.9 mg/dL, sensitivity 0.64, specificity 0.63). In contrast, CRP, interleukin-6, ferritin, LDH, D-dimers, and total fibrinogen had weaker associations with COVID-19 disease severity (all ROC curves with lower AUCs). Thus, GPF may be a useful inflammatory marker of COVID-19 respiratory disease severity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HumansFibrinogenBiomarkersC-Reactive ProteinPatient AcuityRetrospective Studies

Stichwörter der Autor:innen

BiomarkersCOVID-19Disease progressionFibrinogenRespiratory distress syndrome

Substanzen

FibrinogenBiomarkersC-Reactive Protein

Autor:innen und Institutionen

  • Department of Surgery, University of California, San Francisco, CA, USA.
  • Theragen Biologics Pvt Ltd, Chennai, India.
  • Fiona Stanley Fremantle Hospital Group, Murdoch, Western Australia, Australia; Edith Cowan University, Joondalup, Western Australia, Australia.
  • Department of Surgery, Oregon Health & Science University, Portland, OR, USA.
  • Gamma Diagnostics, Portland, OR, USA.
  • MagGenome Pvt Ltd, Chennai, India.

Förderung

  • NIGMS NIH HHS

Zitieren

APA

Kornblith, L. Z., Sadhanandhan, B., Arun, S., Long, R., Johnson, A. J., Noll, J., Ramchand, C. N., Olynyk, J. K., & Farrell, D. H. (2023). γ′ fibrinogen levels as a biomarker of COVID-19 respiratory disease severity. Blood Cells, Molecules, and Diseases. https://doi.org/10.1016/j.bcmd.2023.102746

Vancouver

Kornblith LZ, Sadhanandhan B, Arun S, Long R, Johnson AJ, Noll J, et al. γ′ fibrinogen levels as a biomarker of COVID-19 respiratory disease severity. Blood Cells, Molecules, and Diseases. 2023. doi:10.1016/j.bcmd.2023.102746

BibTeX
@article{Kornblith2023,
  author = {Kornblith, Lucy Z and Sadhanandhan, Bindhya and Arun, Sreepriya and Long, Rebecca and Johnson, Alicia J and Noll, Jamie and Ramchand, C N and Olynyk, John K and Farrell, David H},
  title = {γ′ fibrinogen levels as a biomarker of COVID-19 respiratory disease severity},
  journal = {Blood Cells, Molecules, and Diseases},
  year = {2023},
  doi = {10.1016/j.bcmd.2023.102746}
}
Kostenlos starten →